Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and/or refractory multiple myeloma

Yubin Kang, Pasupathi Sundaramoorthy, Cristina Gasparetto, Daniel Feinberg, Shengjun Fan, Gwynn D. Long, Emily A. Sellars, Anderson Garrett, Sascha A. Tuchman, Brandi Reeves, Zhiguo Li, Bei Liu, Besim Öğretmen, Lynn W. Maines, Vered Katz Ben-Yair, Charles D. Smith, Terry F. Plasse